Indian Immunologicals developing oral cervical cancer vaccine
This article was originally published in Scrip
Executive Summary
Indian Immunologicals (IIL) is developing a third-generation live-vector oral cervical cancer vaccine. If successful, the prophylactic vaccine has the potential to significantly improve compliance and coverage cost-effectively.